Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children younger than 5 years old, a move that would add another barrier ...

Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax has experienced a significant decline in its stock price, dropping by 19.26% over the past week. This downturn comes despite recent positive developments, including a $175 million milestone ...

The number of people with COVID-19 in the U.S. is low but increasing, according to Centers for Disease Control and Prevention (CDC) data released Friday. COVID-19 is trending up in many mid-Atlant… ...

Michigan health officials are still recommending COVID vaccines for nearly everyone, despite federal changes.